nuclear β-catenin positivity
nuclear β-catenin positivity
Overview
Nuclear β-catenin positivity refers to the immunohistochemically or biochemically detected accumulation of β-catenin protein within the nucleus of a cell, a hallmark of aberrant canonical Wnt/β-catenin pathway activation. Under homeostatic conditions, β-catenin (encoded by the CTNNB1 gene) serves a dual role: it participates in cell–cell adhesion as a component of the E-cadherin–catenin complex at the plasma membrane, and it functions as a latent transcriptional co-activator held in check by a cytoplasmic destruction complex that includes GSK3β, APC, Axin, and casein kinase 1. Phosphorylation by GSK3β targets β-catenin for ubiquitin-proteasome-mediated degradation. When Wnt ligands engage their receptors, this destruction complex is inactivated, β-catenin accumulates in the cytoplasm, and the protein translocates to the nucleus, where it associates with TCF/LEF transcription factors—most notably TCF4—to drive expression of proliferative oncogenes such as MYC (c-MYC) and CCND1 (Cyclin D1).
Nuclear β-catenin positivity is therefore both a diagnostic marker and a mechanistic indicator of Wnt pathway dysregulation. It is routinely detected by immunohistochemistry in a wide spectrum of neoplastic and non-neoplastic conditions, ranging from desmoid fibromatosis and colorectal adenomas driven by CTNNB1 or APC mutations, to hepatocellular carcinoma, diffuse large B-cell lymphoma (DLBCL), glioblastoma, breast cancer, and lung adenocarcinoma. Beyond oncology, aberrant nuclear β-catenin activity has been documented in metabolic diseases such as type 2 diabetes, degenerative conditions including intervertebral disc degeneration and Age-related osteogenic failure, and ischemic neurological injury, underscoring the broad pathophysiological reach of this signaling node.
Focus of Latest Publications
Recent publications have continued to use nuclear β-catenin positivity as a readout of active Wnt/β-catenin signaling across several disease models, most often in cancer. In colorectal cancer, a study of valproic acid plus zebularine reported altered CTNNB1/β-catenin expression in colon cancer cells, with protein localization assessed in both cytoplasm and nucleus alongside morphological changes consistent with programmed cell death. The combination treatment reduced proliferation and was associated with downregulation of CTNNB1 in a dose-dependent manner. In diffuse large B-cell lymphoma, HDAC inhibition was linked to suppression of β-catenin signaling through BTG1, which inhibited formation of the β-catenin/TCF4 transcriptional complex and reduced downstream targets such as MYC and Cyclin D1.
Other studies connected nuclear β-catenin positivity to therapy response and resistance mechanisms. In glioblastoma, inhibition of miR-25-3p consistently suppressed β-catenin and re-induced FBXW7 expression in patient-derived cell lines, with some lines showing enhanced temozolomide sensitivity and reduced invasiveness. In triple-negative breast cancer, nitazoxanide was proposed as a ferroptosis inducer acting through dual disruption of iron homeostasis and the β-catenin/GPX4 axis, although the abstract did not provide detailed outcome data. In colorectal cancer immune evasion, β-catenin palmitoylation by ZDHHC5 stabilized the β-catenin/TCF4 complex, increasing SLC7A11 and PD-L1 expression to suppress immunogenic ferroptosis and inhibit CD8+ T-cell activity; blocking this palmitoyl-switch with β-cat-oxazole restored anti-tumor immunity and reduced tumor growth.
Beyond oncology, nuclear β-catenin positivity was also examined in metabolic, neurological, and skeletal contexts. In type 2 diabetes, CTNNB1 was identified as a differentially expressed gene, with reduced serum and pancreatic β-catenin levels in patients and diabetic mice; immunofluorescence showed spatial overlap between CTNNB1 and DLK1 in pancreatic islet cells, supporting a potential interaction. In ischemic stroke, resveratrol reversed the stroke-induced reduction in β-catenin and other Wnt proteins while preserving blood–brain barrier integrity. In osteoporosis, melatonin increased Wnt3a and β-catenin expression in osteoblast-related models and improved bone-related outcomes, while in a study of ginger-processed Magnolia bark, CTNNB1 emerged as a core network target among gastrointestinal disease-related nodes.